- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04567875
Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma (Apa-CARDIO1)
This is a prospective observational study on a cohort of patients with castration-resistant prostate cancer M0, treated with Apalutamide, at the Oncology Unit of the "Andrea Tortora" Hospital of Pagani. Data will be collected on the patient's clinical history and the treatments carried out until the start of therapy with Apalutamide. At that time the study will be described to the patient and informed consent will be given.
In case of a favorable opinion from the patient, the CRF will be filled in. Patients with CRPC M0 treated with Apalutamide, belonging to the Oncology Unit of the Pagani Hospital "Andrea Tortora" and of the other Oncology Units of the ASL of Salerno (Hospital of Vallo della Lucania) will be studied with the possibility of enrollment also from other Centers outside the Salerno ASL.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The CRPC M0 patient will be identified by PET PSMA, or CT scan and Bone Scanning at the clinician's discretion based on the physical examination performed at the patient's first access. The reassessment of the disease status is to be repeated by PET-PSMA, CT scan or bone scan (in relation to the examination carried out at baseline) in a period of time ranging from 6 to 12 months after the first access, based on the assessment of the health status of the patient and tolerability to treatment after careful evaluation by the clinician. The blood chemistry routine including CBC with white blood cell formula will be repeated every 30 days. The patient will be provided with a blood pressure monitoring diary every 30 days. The measurement of cardiac markers will be performed every 60 days. The evaluation of the cardiological function will be carried out by means of ECG, echocardiography with determination of the LVEF, 24-hour Holter blood pressure every 6 months. Bone mineral density assessment will be monitored by MOC-DEXA every 6 months. Possible drug interactions with Apalutamide will be identified.
Primary objective:
-Evaluation of arterial hypertension, by periodic measurement of blood pressure every week (1-3 times), creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months, with stratification of patients under treatment according to the degree of AI found.
Secondary objectives:
- Evaluation of cardiological toxicity, through the execution of ECG, periodic echocardiography for the evaluation of the ejection fraction of the left ventricle, cardiac markers (troponin, CK-MB, pro-BNP)
- Assessment of the biochemical response, such as a 50% reduction in total PSA compared to baseline in patients receiving apalutamide;
- Evaluation of the change in blood chemistry parameters in the patient being treated with Apalutamide;
- Relationship between changes in blood chemistry parameters and time to the onset of metastases, assessed by PET PSMA or bone scan or CT scan;
- Relationship between changes in blood chemistry parameters and overall survival;
- Relationship between changes in blood chemistry parameters and occurrence of serious adverse events;
- Association between basophil counts and appearance of skin rash;
- Evaluation of drug interactions with Apalutamide.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Salerno
-
Pagani, Salerno, Italy, 84016
- Recruiting
- Oncology Unit, Hospital Andrea Tortora
-
Contact:
- Data Manager Oncology Unit
- Phone Number: +390819213683
- Email: trialclinici.oncopagani@gmail.com
-
Contact:
- Data Manager Oncology Unit
- Phone Number: +390819213658
- Email: trialclinici.oncopagani@gmail.com
-
Pagani, Salerno, Italy, 84016
- Recruiting
- Oncology Unit, Ospedale Andrea Tortora
-
Principal Investigator:
- Giuseppe Di Lorenzo
-
Contact:
- Data Manager Oncology Unit
- Phone Number: +360819213683
- Email: trialclinici.oncopagani@gmail.com
-
Contact:
- Data Manager Oncology Unit
- Phone Number: +360819213658
- Email: trialclinici.oncopagani@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- CRPC patients without evidence of distant metastasis are eligible
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CRPC patients
CRPC patients without evidence of distant metastasis are eligible
|
No Intervention on patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of arterial hypertension, by creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months
Time Frame: Almost 1 year
|
Evaluation of arterial hypertension, by creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months
|
Almost 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of biochemical response, such as 50% change in total PSA from baseline in patients receiving apalutamide
Time Frame: Almost 1 year
|
Assessment of biochemical response, such as 50% change in total PSA from baseline in patients receiving apalutamide
|
Almost 1 year
|
Relationship between changes in blood chemistry parameters and time to onset of metastases, assessed by PET PSMA or bone scan or CT scan
Time Frame: Almost 1 year
|
Relationship between changes in blood chemistry parameters and time to onset of metastases, assessed by PET PSMA or bone scan or CT scan
|
Almost 1 year
|
Relationship between changes in blood chemistry parameters and overall survival
Time Frame: Almost 1 year
|
Relationship between changes in blood chemistry parameters and overall survival
|
Almost 1 year
|
Relationship between changes in blood chemistry parameters and occurrence of serious adverse events
Time Frame: Almost 1 year
|
Relationship between changes in blood chemistry parameters and occurrence of serious adverse events
|
Almost 1 year
|
Association between basophil count and appearance of skin rash
Time Frame: Almost 1 year
|
Association between basophil count and appearance of skin rash
|
Almost 1 year
|
Evaluation of drug interactions with Apalutamide
Time Frame: Almost 1 year
|
Evaluation of drug interactions with Apalutamide
|
Almost 1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Wounds and Injuries
- Genital Neoplasms, Male
- Prostatic Diseases
- Drug-Related Side Effects and Adverse Reactions
- Radiation Injuries
- Hypertension
- Prostatic Neoplasms
- Cardiotoxicity
Other Study ID Numbers
- APA-CARDIO_PAG_01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Castration-resistant Prostate Cancer
-
Nuvation Bio Inc.WithdrawnProstate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic NeoplasmsUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Astellas Pharma IncPfizerCompletedCastration-resistant Prostate CancerJapan
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Translational Research Center for Medical Innovation...CompletedCastration Resistant Prostate Cancer (CRPC)
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
Clinical Trials on No Intervention on patients
-
Ospedale Andrea Tortora di PaganiUnknown
-
Aristotle University Of ThessalonikiRecruitingMetalloproteinase SNPs -1575 G/A MMP-2, 836 A/G MMP-9 and -77 A/G MMP-13 and Risk for Developing Knee Osteoarthritis in Greek PopulationGreece
-
University Hospital of CologneCompletedAllergic RhinitisGermany
-
University Hospital Southampton NHS Foundation...Portsmouth Hospitals NHS Trust; University of DerbyRecruitingDepression | Anxiety | Emotional Disorder | Psychological Distress | Emotions | Coping Behavior | Emotional Distress | Psychological Adjustment | Psychological Stress | Psychological | Psychosocial Problem | Psychological Disorder | Emotional Dysfunction | Severe Eosinophilic Asthma | Psychosocial Stressor | Adjustment | Adjustment...United Kingdom
-
Marmara UniversitySaglik Bilimleri UniversitesiCompletedOral Health in Children With Inflammatory Bowel DiseaseTurkey
-
Swiss SOS Study GroupUniversitätsklinik für Neurochirurgie, Inselspital Bern; Département des Neurosciences... and other collaboratorsTerminatedStroke | Cognitive Impairment | Subarachnoid Hemorrhage | Delayed Cerebral Ischemia | Complication | Cognitive Deficit | Cognitive Deterioration | Cognitive Deficits Following Cerebral InfarctionSwitzerland
-
Ain Shams UniversityCompleted
-
Wellcome Trust Liverpool Glasgow Centre for Global...Professor David Lalloo; Professor Hamish Simpson; Professor William J Harrison; Professor Sithombo MaqungoUnknownFracture Healing in HIV-positive PatientsSouth Africa
-
Philipps University Marburg Medical CenterCompleted
-
University Hospital, MontpellierAstraZenecaUnknownALLERGIC OR HYPERSENSITIVITYFrance